PROK - ProKidney Corp Debt to Book Capitalization Ratio

ProKidney Corp. (PROK) is at the start of a multi-year biotechnology investment cycle, where success depends on therapy trials and liquidity. The business relies on REACT kidney tissue regeneration technology, which will ensure pricing power amid inelastic demand. The market price on the GURU.Markets platform, as confirmed by this chart, is 0.00, supported by the innovative potential of US capacities for developing cell-based therapies.

PROK (ProKidney Pharma) Debt to Book Value history from 04/28/2023 to 10/27/2026

ProKidney Corp (PROK) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price ProKidney Corp.|PROK - Analyst Consensus Forecast

- market capitalization data:

Market Value ProKidney Pharma|PROK - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share ProKidney|PROK - Company Net Assets|Market Capitalization to Book Value Ratio prokidney.com|PROK - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio ProKidney Corp.|PROK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ProKidney Inc.|PROK - Company Aggregate Debts|Debts to Book Capitalization ProKidney Pharma

Fundamental company analysis:ProKidney Corp.

Investors always balance the desire to maximize profits with the necessity of controlling hidden leverage. By analyzing the dynamics of the debt-to-capitalization ratio, you assess the proportion of borrowed funds within the balance sheet structure, where a decrease in this metric confirms the financial stability of ProKidney Corp. (PROK) during the development of costly cell therapy aimed at capturing a monopoly segment of the nephrology market.

Competitors of ProKidney Corp.